Navigation Links
ASPIRE Phase III trial of vaginal ring to prevent HIV completes enrollment of 2,629 women
Date:6/26/2014

l beyond one year, the team determined a target enrollment of 2,600 participants would be sufficient to meet its objectives. Because the ASPIRE protocol was designed to accommodate new information as it becomes available, both the Study Monitoring Committee and the independent Data Safety and Monitoring Board (DSMB) that conducts routine reviews of the study were in agreement with the team. Indeed, at its most recent review on May 31, the DSMB recommended that the study, with 2,555 women enrolled to date, could stop screening new women and close enrollment soon thereafter.

When ASPIRE concludes in June or July 2015, all women will have used their assigned study product (placebo ring or dapivirine ring) for at least one year, a regulatory requirement, and some women will have used the ring two years or longer. (Because one of the main objectives of The Ring Study is to evaluate long-term safety of the ring, all women enrolled in that trial will use the monthly ring for two years.)

IPM will seek regulatory approval and licensure for the ring based on the results of The Ring Study and ASPIRE as well as several smaller safety studies taking place in the United States and Europe. A nonprofit product developer based in Silver Spring, Md., IPM is developing dapivirine for use as a vaginal microbicide in developing countries through a royalty-free licensing agreement with Janssen R&D Ireland.

Dapivirine, also known as TMC-120, belongs to a class of ARVs called non-nucleoside reverse transcriptase inhibitors (NNRTIs) that bind to and disable HIV's reverse transcriptase enzyme, a key protein needed for HIV replication. The dapivirine ring, made of a flexible silicone material, allows the drug to be slowly released from the ring over time. IPM's studies have shown that the ring can deliver dapivirine to vaginal tissue for a month or longer, with minimal concentration elsewhere in the body. Its studies to date have also shown that use of the dapivi
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-641-8940
Microbicide Trials Network
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. MyPuress Announces Expansion into Canadian Market with Release of Aspiree Product Line
2. ALS patients differ on treatment choices in later phases of disease
3. Reach2HD, a Phase II study in Huntingtons disease, launched
4. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
5. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
6. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
7. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
8. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
9. Positive results from Phase 1/2 stem cell trial reported
10. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
11. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... New findings about brain rhythms could lead to the development ... team at Massachusetts General Hospital found that a brain rhythm ... form during sleep, where it becomes more intense at certain ... being awakened by noise or other disturbances. To test ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... have discovered that a natural product isolated from a traditional ... lei gong teng, and used for hundreds of years to ... control machinery in the cell. The report, published as a ... Biology, suggests that the natural product could be a ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) ... painkillers experience cognitive problems such as confusion, disorientation and ... cancer patients from 17 health-care centers around Europe indicated ... morphine scored lower on observer-rated mental tests measuring orientation ...
... vast literature on cancer to produce a next-generation view ... cells. These hallmarks of the disease provide a ... influence biomedical researchers in their quest for new cancer ... Hanahan of cole Polytechnique Fdrale in Switzerland and Robert ...
Cached Medicine News:Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 2Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 3Health News:In search of cancer's common ground: A next-generation view 2
(Date:10/2/2014)... Oct. 2, 2014   Softworld, Inc. announced today ... practice solely focused on the specific needs of pharmaceutical, ... Softworld has already been highly successful in the clinical ... capabilities to support the quality, regulatory, and validation space. ... a combination of the current Biometric team and the ...
(Date:10/2/2014)... 2, 2014   Mast Therapeutics, Inc. (NYSE ... Edwin L. Parsley , D.O. has joined the ... President.  Dr. Parsley has been actively engaged ... in February 2014.  He has served as Mast,s interim ... Medical Officer of Aires since April 2011.  Dr. Parsley ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... June 20, 2011 Boston Scientific Corporation (NYSE: ... its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 ... wide range of peripheral angioplasty procedures.  The Company plans ... and other international markets. Boston Scientific ...
... Panacea Global Inc., ("the Company") (OTCQB: PANG), a biopharmaceutical ... diagnose and monitor cancer, today announced the change of the ... On June 15, 2011, the trading symbol for the Company,s ... was changed from MLXG to PANG.  This change was made ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 2Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 3Panacea Global, Inc. Files Form 8-K to Announce Name Change; Trading Symbol Changes from MLXG to PANG 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: